We are investigating whether the directors of TherapeuticsMD (ticker: TXMD) (“TXMD”) acted in the best interests of TXMD shareholders in approving the sale of TXMD to EW Healthcare Partners (“EWHP”) for $10.00 per share in cash.
If you remain a TXMD shareholder and have questions about your legal rights, please contact our firm using the link below to discuss your options at no charge.
Why is there an investigation?
On May 31, 2022, TXMD announced that it had agreed to be acquired by EWHP for $10.00 per share in cash in a tender offer. The transaction was unanimously approved by TXMD’s Board of Directors (“Board”).
Our investigation concerns whether TXMD’s Board acted in the best interests of TXMD shareholders in approving the sale to EWHP, including whether the acquisition price adequately compensates TXMD shareholders, and whether all information regarding approval of the transaction has been fully disclosed.
In particular, the buyout price is less than the price at which TXMD was trading less than a month ago after a 1:50 reverse stock split on May 9, 2022.